Gilead Sciences | GILD - Despesas Operacionais

Preço das Ações
128.84
Mudança Diária
-0.42 -0.32%
Mensal
-5.50%
Anual
20.93%
Q2 Previsão
127.61




Despesas Operacionais Alterar Data
AbbVie USD 10.27B 538M 2026-03
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
ALKERMES USD 326.44M 1.41B 2025-12
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
Amgen USD 5.9B 773M 2025-12
Biogen USD 1.96B 69.6M 2026-03
BioMarin Pharmaceutical USD 676.18M 131.65M 2025-12
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Coherus Biosciences USD 51.83M 2.48M 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
GlaxoSmithKline GBP 5.34B 1.85B 2026-03
Glaxosmithkline GBP 9.17B 1.4B 2025-12
Incyte USD 5.62B 4.5B 2026-03
J&J USD 17.44B 1.53B 2026-03
Merck USD 10.16B 558M 2025-12
Moderna USD 1.54B 259M 2025-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
Novartis USD 9.8B 61M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
PTC Therapeutics USD 246.3M 38.78M 2025-12
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sanofi EUR 9.31B 1.2B 2026-03
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
United Therapeutics USD 804.8M 5.79B 2025-12
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12